Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Page Menu

Sanjay Ram

UMassMed Faculty Page

Inventions:

Title: Factor H/Fc Chimeric Molecules as Anti-pathogen Immunoadhesins. UMMS15-30, Patent Pending. 

Title: NEISSERIA GONORRHOEAE THERAPEUTIC BASED ON CMP-NONULOSONATE SUGARS. UMMS14-77; Patent 9,765,106.

  • Invention encompasses a new strategy to combat drug-resistant gonorrhea.  This technology manipulates the lipooligosacchride capping of gonococci, thereby decreasing it’s fitness and virulence. By interrupting the sialic acid mediated pathogenesis that contributes to drug-resistance, this intervention can render gonorrhoeae sensitive to killing by the innate immunity system. 

Title: COMPLEMENT FACTOR H-BASED ASSAYS FOR SERUM BACTERICIDALACTIVITY AGAINST NEISSERIA MENINGITIDISUMMS09-17; Patent 8,476,032

  • This invention discloses an assay method for detecting anti-Neisseria antibodies. Human factor H (fH) is a virulence factor that helps Neisseria to resist complement-mediated killing, thus circumventing the host’s innate immune response. Higher serum fH levels may correlate to patient susceptibility to infection. Neisserial factor H binding protein (fHBp) can be hindered by a human amino acid sequence revealed in the present technology, to facilitate accurate detection of Neisseria that exceeds the capability of existing methods. A reaction mixture containing bactericidal anti-Neisseria antibodies, a fH polypeptide comprising an amino acid sequence of human Short Consensus Repeat 6 sources of non human complement (SCR), and a Neisseria bacterium. This invention additionally discloses an animal model of Neisseria infection.

Title: METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIEUMMS09-08; Patent 9,475,864

  • This invention reports the discovery of serum IgG of different individuals that block antibody (Ab) activity targeted against Neisseria membrane lipoprotein H.8. Blocking Ab activity may predispose such individuals to developing invasive disease with N. meningtitidis or decrease the efficacy of vaccines. This finding can explain the variability between individual susceptibility and provide new avenue for treatment and increasing efficacy of existing treatments.

 

Innovation TopicsBiologicsInfectious DiseaseNeisseria gonorrhoeaeImmunotherapyDrug resistanceSmall MoleculesSexually transmitted disease (STD), GonorrheaDrug resistanceNew antibody treatmentAntibiotics/Antibiotic treatmentN. meningitidesVaccines